The five main psychopharmacological drug groups are reviewed in respect of their effects on the pharmaco-electroencephalogram (pharmaco-EEG), with special consideration given to drug profiling by topographic brain mapping. In addition, the CNS effects of sertraline (100, 200, and 400 mg), zimelidine (100 mg), and placebo were studied. The pharmaco-EEG profiles of both sertraline (100 mg) and zimelidine were indicative of vigilance-enhancement seen after desipramine-type antidepressants; with higher sertraline dosages there was a change toward the sedation associated with imipramine-type antidepressants. Both sertraline (100 mg) and zimelidine improved psychometric performance, although some deterioration occurred with higher sertraline (200 and 400 mg) doses. Psychophysiological variables showed dose-dependent changes in CNS activation and pupillary dilatation. Adverse effects were minimal with both sertraline (100 mg) and zimelidine, while nausea and vomiting increased with sertraline 200 and 400 mg.

Download full-text PDF

Source

Publication Analysis

Top Keywords

sertraline 100
16
200 400
12
100 zimelidine
12
drug profiling
8
special consideration
8
sertraline
8
higher sertraline
8
sertraline 200
8
0
5
profiling computed
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!